Search Results

The STC Amphetamine-Specific Intercept™ MICRO-PLATE EIA is intended for use by clinical laboratories in the qualitative determination of amphetamine in oral fluid collected with the Intercept™ DOA Oral Specimen Collection Device. For In Vitro Diagnostic Use.

The STC Amphetamine-Specific Intercept™ MICRO-PLATE EIA is a competitive micro-plate immunoassay for the detection of amphetamine in oral fluid collected with the Intercept™ DOA Oral Specimen Collection Device. Specimen or standard is added to an EIA well in combination with an enzyme-labeled hapten derivative. In an EIA well containing an oral fluid specimen positive for amphetamine, there is a competition between the drug and the enzyme-labeled hapten to bind the antibody fixed onto the EIA wells are then washed, substrate is added, and color is produced. The absorbance measured for each well at 450 mm is inversely proportional to the amount of amphetamine present in the specimen or calibrator/control.

Here's an analysis of the provided text, outlining the acceptance criteria and study details for the STC Amphetamine-Specific Intercept™ MICRO-PLATE EIA:

1. Table of Acceptance Criteria and Reported Device Performance

The document doesn't explicitly state "acceptance criteria" in a numerical or pass/fail format for clinical performance. Instead, it presents various analytical performance characteristics and clinical study results. For the purpose of this response, I infer the "acceptance criteria" based on the comparisons made to the predicate device and the presented study outcomes.

Ask a specific question about this device